Literature DB >> 12049986

Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions.

Jadranka Kuljanin1, Ivana Janković, Jovan Nedeljković, Dusica Prstojević, Valentina Marinković.   

Abstract

The formation of the complex between alendronate, non-chromophoric bisphosphonate drug important for the treatment of a variety of bone diseases, and iron(III) chloride in perchloric acid solution was studied. The stoichiometric ratio of alendronate to Fe(III) ions in the chromophoric complex was determined to be 1:1. The conditional stability constant was logK'(ave)=4.50(SD=0.15), indicating that the Fe(III)-alendronate complex is a complex of medium stability. The optimum conditions for this reaction were ascertained and a spectrophotometric method was developed for the determination of alendronate in the concentration range 8.1-162.5 microg ml(-1), the detection limit being 2 microg ml(-1). The method was validated for the direct determination of alendronate in tablet dosage formulations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12049986     DOI: 10.1016/s0731-7085(02)00021-3

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  27 in total

1.  The biocompatibility of calcium phosphate cements containing alendronate-loaded PLGA microparticles in vitro.

Authors:  Yu-Hua Li; Zhen-Dong Wang; Wei Wang; Chang-Wei Ding; Hao-Xuan Zhang; Jian-Min Li
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-14

2.  Expression of the mannose receptor CD206 in HIV and SIV encephalitis: a phenotypic switch of brain perivascular macrophages with virus infection.

Authors:  Gerard E Holder; Christopher M McGary; Edward M Johnson; Rubo Zheng; Vijay T John; Chie Sugimoto; Marcelo J Kuroda; Woong-Ki Kim
Journal:  J Neuroimmune Pharmacol       Date:  2014-08-22       Impact factor: 4.147

3.  Synthesis, characterization and osteoconductivity properties of bone fillers based on alendronate-loaded poly(ε-caprolactone)/hydroxyapatite microspheres.

Authors:  Jianhong Chen; Yun Luo; Liangqing Hong; You Ling; Jun Pang; Youqiang Fang; Kun Wei; Xin Gao
Journal:  J Mater Sci Mater Med       Date:  2011-02-12       Impact factor: 3.896

4.  Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.

Authors:  Ehud Segal; Huaizhong Pan; Liat Benayoun; Pavla Kopečková; Yuval Shaked; Jindřich Kopeček; Ronit Satchi-Fainaro
Journal:  Biomaterials       Date:  2011-03-22       Impact factor: 12.479

5.  Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.

Authors:  Rebecca S Hayden; Moritz Vollrath; David L Kaplan
Journal:  Acta Biomater       Date:  2013-10-01       Impact factor: 8.947

6.  Complexation of bisphosphonates with ytterbium(III): application of phosphate and ATP detection assay based on Yb(3+)-pyrocatechol violet.

Authors:  Ernestas Gaidamauskas; Helen Parker; Boris A Kashemirov; Alvin A Holder; Kanokkarn Saejueng; Charles E McKenna; Debbie C Crans
Journal:  J Inorg Biochem       Date:  2009-09-20       Impact factor: 4.155

7.  Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates.

Authors:  Huaizhong Pan; Monika Sima; Pavla Kopecková; Kuangshi Wu; Songqi Gao; Jihua Liu; Dong Wang; Scott C Miller; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2008-05-28       Impact factor: 4.939

8.  Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications.

Authors:  Xuetao Shi; Yingjun Wang; Li Ren; Yihong Gong; Dong-An Wang
Journal:  Pharm Res       Date:  2008-11-01       Impact factor: 4.200

9.  Effects of polycaprolactone on alendronate drug release from Mg-doped hydroxyapatite coating on titanium.

Authors:  Susmita Bose; Ashley A Vu; Khalid Emshadi; Amit Bandyopadhyay
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2018-02-24       Impact factor: 7.328

10.  Spectrophotometric Determination of Risedronate in Pharmaceutical Formulations via Complex Formation with Cu (II) Ions: Application to Content Uniformity Testing.

Authors:  M I Walash; M E-S Metwally; M Eid; R N El-Shaheny
Journal:  Int J Biomed Sci       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.